지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
등록된 정보가 없습니다.
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn’s disease
Intestinal research
2018 .01
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
Journal of Korean Medical Science
2017 .01
Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
Intestinal research
2017 .01
Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
Gut and Liver
2017 .01
Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Intestinal research
2018 .01
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis
대한류마티스학회지
2024 .01
Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Gut and Liver
2016 .01
Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn’s disease
Intestinal research
2018 .01
Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Intestinal research
2018 .01
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Gut and Liver
2021 .09
Focus on Endoscopic Resection
대한외과학회 학술대회 초록집
2019 .10
Endoscopic Treatment of Subepithelial Tumors
Clinical Endoscopy
2018 .01
Update of endoscopic management of Crohn’s disease strictures
Intestinal research
2020 .01
Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study
Yonsei Medical Journal
2020 .01
Efficacy and Safety of Anti-Tumor Necrosis Factor- Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-Analysis
Yonsei Medical Journal
2022 .02
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Intestinal research
2022 .01
Influence of anti-tumor necrosis factor-alpha therapy on pregnant women with inflammatory bowel disease and their children’s immunity
Intestinal research
2019 .01
Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
Yonsei Medical Journal
2023 .02
Clinical, endocrinological, and molecular features of four Korean cases of cytochrome P450 oxidoreductase deficiency
Annals of Pediatirc Endocrinology & Metabolism
2020 .01
0